These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 28710053)

  • 1. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
    Dahhan T; Balkenende EME; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; van Golde RJT; Schipper I; Louwé LA; Cantineau AEP; Smeenk JMJ; de Bruin JP; Reddy N; Kopeika Y; van der Veen F; van Wely M; Linn SC; Goddijn M
    Contemp Clin Trials; 2017 Oct; 61():96-100. PubMed ID: 28710053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
    Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
    Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
    Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
    Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to ovarian stimulation in patients facing gonadotoxic therapy.
    Johnson LN; Dillon KE; Sammel MD; Efymow BL; Mainigi MA; Dokras A; Gracia CR
    Reprod Biomed Online; 2013 Apr; 26(4):337-44. PubMed ID: 23415997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
    Pereira N; Hancock K; Cordeiro CN; Lekovich JP; Schattman GL; Rosenwaks Z
    Gynecol Endocrinol; 2016 Oct; 32(10):823-826. PubMed ID: 27114051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes.
    Turan V; Bedoschi G; Emirdar V; Moy F; Oktay K
    Reprod Sci; 2018 Jan; 25(1):26-32. PubMed ID: 28874104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
    Fatum M; McVeigh E; Child T
    Hum Fertil (Camb); 2013 Dec; 16(4):235-40. PubMed ID: 23863119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients.
    Shulman Y; Almog B; Kalma Y; Fouks Y; Azem F; Cohen Y
    J Assist Reprod Genet; 2021 Mar; 38(3):743-750. PubMed ID: 33409757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women.
    Checa Vizcaíno MA; Corchado AR; Cuadri ME; Comadran MG; Brassesco M; Carreras R
    Reprod Biomed Online; 2012 Jun; 24(6):606-10. PubMed ID: 22503276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
    Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
    Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
    Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
    Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients.
    Turan V; Bedoschi G; Moy F; Oktay K
    Fertil Steril; 2013 Dec; 100(6):1681-5.e1. PubMed ID: 24055050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
    Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
    Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial.
    Letourneau J; Juarez-Hernandez F; Wald K; Ribeiro S; Wang A; McCulloch CE; Mok-Lin E; Dolezal M; Chien AJ; Cedars MI; Rosen M
    J Assist Reprod Genet; 2021 Sep; 38(9):2455-2463. PubMed ID: 34312774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fertility preservation options in breast cancer patients.
    Kasum M; von Wolff M; Franulić D; Čehić E; Klepac-Pulanić T; Orešković S; Juras J
    Gynecol Endocrinol; 2015; 31(11):846-51. PubMed ID: 26370157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer?
    Revelli A; Porcu E; Levi Setti PE; Delle Piane L; Merlo DF; Anserini P
    Gynecol Endocrinol; 2013 Nov; 29(11):993-6. PubMed ID: 24000936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy.
    Danis RB; Pereira N; Elias RT
    Curr Pharm Biotechnol; 2017 Nov; 18(8):609-613. PubMed ID: 28786354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fertility preserving methods in women with breast cancer before gonadotoxic therapy].
    Halászová N; Crha I; Huser M; Weinberger V; Žáková J; Ješeta M; Lousová E; Filipinská E; Ventruba P
    Ceska Gynekol; 2017; 82(4):287-292. PubMed ID: 28925272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer.
    Oktay K; Turan V; Bedoschi G; Pacheco FS; Moy F
    J Clin Oncol; 2015 Aug; 33(22):2424-9. PubMed ID: 26101247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
    Oktay K; Buyuk E; Libertella N; Akar M; Rosenwaks Z
    J Clin Oncol; 2005 Jul; 23(19):4347-53. PubMed ID: 15824416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.